T1	Participants 110 148	adults with major depressive disorder.
T2	Participants 348 394	patients with major depressive disorder (MDD).
T3	Participants 571 712	Adults aged 18-75 years with MDD (DSM-IV-TR) and Montgomery-Asberg Depression Rating Scale (MADRS) total score â‰¥ 26 were randomized (1:1:1)
T4	Participants 1141 1283	RESULTS Of the 1,111 subjects screened, 469 subjects were randomized: 160 to placebo, 157 to vortioxetine 10 mg, and 152 to vortioxetine 15 mg
